Skip to main content
Zenlabs Ethica Limited logo

Zenlabs Ethica Limited — Investor Relations & Filings

Ticker · 530697 ISIN · INE546F01013 LEI · 335800H7G5DAVOF15O84 BSE.NS Manufacturing
Open in API
Filings indexed 6 across all filing types
Latest filing 2026-05-29 Regulatory Filings
Country IN India
Listing BSE.NS 530697

About Zenlabs Ethica Limited

https://www.zenlabsethica.com

Zenlabs Ethica Limited specializes in the manufacturing and marketing of a diverse range of pharmaceutical formulations. The company operates through a robust infrastructure dedicated to producing high-quality healthcare products across various therapeutic segments, including analgesics, anti-inflammatory drugs, antibiotics, and gastrointestinal treatments. Its product portfolio encompasses multiple dosage forms such as tablets, capsules, liquid orals, ointments, and injectables. Zenlabs Ethica emphasizes stringent quality control measures and adheres to international manufacturing standards to ensure the efficacy and safety of its medicinal offerings. The organization provides contract manufacturing services and branded generic products. By leveraging advanced technology and research-driven processes, the company aims to deliver affordable and accessible healthcare solutions to a global patient base.

Recent filings

Filing Released Lang Actions
Declaration regarding non-applicability of the Regulation 23(9) of SEBI (LODR), 2015 in respect of disclosure of related party transaction for the half year ended 31st March 2026.
Regulatory Filings Classification · 85% confidence The document is a formal notice to the stock exchange under SEBI Listing Obligations, stating that the related party transaction disclosure is not applicable for the half-year ended March 31, 2026. It does not contain financial statements or substantive report data, nor is it an officer certification separate from compliance. It is a general regulatory announcement to BSE regarding a compliance exemption, fitting the Regulatory Filings (RNS) category.
2026-05-29 English
Intimation of reappointment of M/s Jaspreet Dhawan & Associates as the secretarial auditor of the company, reappointment of M/s Anu & Associates as the internal auditor of the company and ....
Regulatory Filings Classification · 72% confidence The document is a stock exchange submission under SEBI LODR Regulations detailing the outcome of a board meeting, including the approval of audited financial results for the quarter and year ended March 31, 2026, along with auditor re-appointments and management changes. It does not itself contain the full financial statements but announces their approval and related disclosures. This is a routine regulatory disclosure rather than the full annual report, earnings release with financial metrics, or interim report. Therefore, it falls under General Regulatory Filings (RNS).
2026-05-29 English
Intimation of appointment of Mr. Nikunj Goel as the Company Secretary and the Compliance Officer of the company w.e.f 29 May 2026.
Board/Management Information Classification · 95% confidence The document is an Intimation under SEBI (Listing Obligations & Disclosure Requirements) Regulation 30 notifying the appointment of Mr. Nikunj Goel as Company Secretary & Compliance Officer. It announces a change in senior management rather than providing financial results or being a proxy/material for an AGM. Therefore it fits the ‘Board/Management Information’ category (MANG).
2026-05-29 English
AUDITED FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2026 AND ANY OTHER MATTER WITH THE PERMISSION OF THE CHAIR.
Interim / Quarterly Report Classification · 85% confidence The document is a regulatory compliance filing under SEBI (LODR) Regulation 33 announcing and attaching the company’s audited financial results for the quarter and year ended March 31, 2026. It contains the full line‐by‐line financial statements (P&L, OCI, EPS, etc.) and the independent auditor’s report. This is not just a highlights earnings release, nor is it the full annual report; it is a periodical financial report covering a quarter (with year-to-date) that includes substantive financial data. Accordingly, it fits the definition of an Interim/Quarterly Report. FY 2026
2026-05-29 English
Outcome of the board meeting held on 29th May 2026 for the approval of the audited financial results for the quarter and year ended 31st March 2026 and other related matters.
Interim / Quarterly Report Classification · 85% confidence The document is a formal stock‐exchange filing under SEBI LODR (“Outcome of Board Meeting – Audited Financial Results for the Quarter and Year ended 31st March 2026”). It contains the full audited financial results (income, expenses, profit/(loss), EPS, etc.) for the quarter and year, along with the auditor’s report and board resolutions. This is more than a brief earnings highlight and is a comprehensive quarterly (and year‐to‐date) financial report mandated by regulation. Accordingly, it fits the definition of an Interim/Quarterly Report, not a short earnings release or full annual report. FY 2026
2026-05-29 English
Zenlabs Ethica Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve audited financial results of ....
Regulatory Filings Classification · 85% confidence The document is an intimation to the stock exchange of a Board of Directors meeting per SEBI Listing Regulations, notifying the date and agenda (approval of audited financial results). It is not the results themselves, nor a full financial report, nor a management change. It is a regulatory announcement required for compliance. Thus it falls under general Regulatory Filings (RNS).
2026-05-25 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.